Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Seed round co-led by Wellington Partners and Forbion, with non-dilutive funding from BMBF GO-Bio enables maturation of platform and pipeline towards first clinical evaluation Seamless Therapeutics

Related Keywords

Germany ,Boston ,Massachusetts ,United States ,Wellington ,New Zealand General ,New Zealand ,Netherlands ,Singapore ,German ,Dennis Riedl ,Technische Universit ,Frank Buchholz ,Felix Lansing ,Oxford Immunotec ,Dmitrij Hristodorov ,Desmond James Stephanie ,Roche Ventana ,Dean Of Research ,Perkinelmer ,Trophic Communications ,Boston Scientific ,University Cancer Center ,Wellington Partners ,Medical Systems Biology ,Chief Scientific Officer ,Seamless Therapeutics Both ,Chief Executive Officer ,Seamless Therapeutics ,Managing Partner ,United Nations Principles ,Biogeneration Ventures ,James Stephanie May ,Seamless ,Herapeutics ,Aunches ,Need ,Financing ,Advance ,Ransformative ,Gene ,Editing ,Platform ,Ased ,Programmable ,Precision ,Designer ,Ecombinases ,